Mabion S.A. (MAB) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Mabion S.A. (MAB) has a cash flow conversion efficiency ratio of -0.308x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (zł-12.06 Million ≈ $-3.32 Million USD) by net assets (zł39.09 Million ≈ $10.76 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Mabion S.A. market cap and net worth for the company's overall valuation and market capitalisation.
Mabion S.A. - Cash Flow Conversion Efficiency Trend (2009–2025)
This chart illustrates how Mabion S.A.'s cash flow conversion efficiency has evolved over time, based on yearly financial data.
Mabion S.A. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Mabion S.A. ranked by their cash flow conversion efficiency. Explore Mabion S.A. cash earnings quality to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Inbest Prime IV Inmuebles SOCIMI S.A.
MC:YINB4
|
N/A |
|
Kriti Industries (India) Limited
NSE:KRITI
|
-0.022x |
|
Gol Linhas Aéreas Inteligentes S.A
NYSE:GOLLQ
|
-0.024x |
|
Iconic Worldwide Bhd
KLSE:9113
|
0.028x |
|
Carnival PLC
LSE:CCL
|
0.096x |
|
ALPHA EXPLORATION LTD
F:J0C
|
-0.010x |
|
Urbanfund Corp
V:UFC
|
0.028x |
|
Metallic Minerals Corp
V:MMG
|
-0.327x |
Annual Cash Flow Conversion Efficiency for Mabion S.A. (2009–2025)
The table below shows the annual cash flow conversion efficiency of Mabion S.A. from 2009 to 2025. View latest Mabion S.A. stock price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | zł55.35 Million ≈ $15.23 Million |
zł-41.59 Million ≈ $-11.45 Million |
-0.751x | -310.06% |
| 2024-12-31 | zł111.44 Million ≈ $30.67 Million |
zł39.86 Million ≈ $10.97 Million |
0.358x | +1905.77% |
| 2023-12-31 | zł117.78 Million ≈ $32.41 Million |
zł-2.33 Million ≈ $-642.08K |
-0.020x | -103.90% |
| 2022-12-31 | zł76.51 Million ≈ $21.06 Million |
zł38.84 Million ≈ $10.69 Million |
0.508x | +182.24% |
| 2021-12-31 | zł53.31 Million ≈ $14.67 Million |
zł-32.91 Million ≈ $-9.06 Million |
-0.617x | -235.56% |
| 2020-12-31 | zł-77.39 Million ≈ $-21.30 Million |
zł-35.24 Million ≈ $-9.70 Million |
0.455x | -70.89% |
| 2019-12-31 | zł-21.58 Million ≈ $-5.94 Million |
zł-33.76 Million ≈ $-9.29 Million |
1.564x | +269.28% |
| 2018-12-31 | zł42.14 Million ≈ $11.60 Million |
zł-38.94 Million ≈ $-10.72 Million |
-0.924x | -192.46% |
| 2017-12-31 | zł-54.16 Million ≈ $-14.91 Million |
zł-54.13 Million ≈ $-14.90 Million |
0.999x | +124.49% |
| 2016-12-31 | zł3.73 Million ≈ $1.03 Million |
zł-15.22 Million ≈ $-4.19 Million |
-4.082x | -1433.70% |
| 2015-12-31 | zł127.64 Million ≈ $35.13 Million |
zł-33.97 Million ≈ $-9.35 Million |
-0.266x | -988.98% |
| 2014-12-31 | zł997.84 Million ≈ $274.62 Million |
zł-24.39 Million ≈ $-6.71 Million |
-0.024x | +53.89% |
| 2013-12-31 | zł520.55 Million ≈ $143.26 Million |
zł-27.59 Million ≈ $-7.59 Million |
-0.053x | -615.46% |
| 2012-12-31 | zł1.82 Billion ≈ $502.09 Million |
zł-13.51 Million ≈ $-3.72 Million |
-0.007x | +98.71% |
| 2011-12-31 | zł20.37 Million ≈ $5.60 Million |
zł-11.74 Million ≈ $-3.23 Million |
-0.576x | -794.40% |
| 2010-12-31 | zł21.72 Million ≈ $5.98 Million |
zł-1.40 Million ≈ $-385.19K |
-0.064x | -101.62% |
| 2009-12-31 | zł-74.80K ≈ $-20.59K |
zł-298.41K ≈ $-82.13K |
3.990x | -- |
About Mabion S.A.
Mabion S.A., a biopharmaceutical company, provides contract development, analytics, and manufacturing services for biologics in Poland. It offers drug substance manufacturing, process development, analytics, and cell line development services. The company also provides medicines for cancer, autoimmune diseases, rare diseases, and other diseases. The company was founded in 2007 and is headquartere… Read more